---
title: "688796.SH (688796.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688796.SH/news.md"
symbol: "688796.SH"
name: "688796.SH"
parent: "https://longbridge.com/en/quote/688796.SH.md"
datetime: "2026-05-20T02:40:08.964Z"
locales:
  - [en](https://longbridge.com/en/quote/688796.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688796.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688796.SH/news.md)
---

# 688796.SH (688796.SH) — Related News

### [Biocytogen Clarifies AGM Resolution on RMB1.5 Billion Credit Facilities and Guarantees](https://longbridge.com/en/news/285576023.md)
*2026-05-07T14:40:46.000Z*
> Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has clarified a clerical error in its AGM circular regarding a special res

### [Biocytogen Pharmaceuticals Beijing Q1 Margin Expansion Reinforces Bullish Earnings Narratives](https://longbridge.com/en/news/284431965.md)
*2026-04-28T18:02:03.000Z*
> Biocytogen Pharmaceuticals (Beijing) reported Q1 2026 revenue of ¥433.1 million and basic EPS of ¥0.23, reflecting signi

### [Stock Movement | Biocytogen fell by 10% after performance](https://longbridge.com/en/news/284307669.md)
*2026-04-28T03:55:28.000Z*
> Biocytogen achieved a net profit of 100 million yuan in the first quarter. After the earnings announcement, the stock pr

### [](https://longbridge.com/en/news/284292073.md)
*2026-04-28T01:29:03.000Z*
> The A-share medical services sector strengthened at the beginning of trading, with WuXi AppTec rising over 9%, CHENGDA P

### [Biocytogen invests 1.6 billion yuan to develop a research and development base for animal and antibody drugs](https://longbridge.com/en/news/284284736.md)
*2026-04-28T00:23:00.000Z*
> Biocytogen-B announced an investment of approximately 1.6 billion yuan in the construction of an animal and antibody dru

### [Biocytogen has successfully implemented the "Time Value Compound Interest Model" for global new drug research and development](https://longbridge.com/en/news/284283904.md)
*2026-04-28T00:14:44.000Z*
> Biocytogen has successfully implemented the "time value compounding model" for global new drug research and development,

### [BIOCYTOGEN-B turned a profit of 100 million yuan in the first quarter after a loss](https://longbridge.com/en/news/284180610.md)
*2026-04-27T08:39:00.000Z*
> According to a report from Economic News Agency on the 27th, BIOCYTOGEN-B (Shanghai: 688796) announced a net profit of R

### [Understanding the Market | Biocytogen-B Rises Over 6% Again After Reaching Strategic Cooperation with Sihuan Pharmaceutical to Accelerate Innovative Drug Development in Weight Loss and Other Areas](https://longbridge.com/en/news/282118583.md)
*2026-04-09T01:45:04.000Z*
> Biocytogen-B rose over 6% again, as of the time of publication, up 6.89%, priced at HKD 67.45, with a transaction volume

### [](https://longbridge.com/en/news/281710361.md)
*2026-04-05T12:21:18.000Z*
> This week's largest increase in margin financing balance: Biocytogen margin financing balance: 70 million yuan, balance